Dexmedetomidine Does Not Affect Evoked Potentials During Spine Surgery
Authors:
- Irene RozetIRIrene Rozet
- Julia MetznerJMJulia Metzner
- Marcia BrownMBMarcia Brown
- Miriam M. TreggiariMTMiriam M. Treggiari
- Jefferson C. SlimpJSJefferson C. Slimp
- Greg KinneyGKGreg Kinney
- Deepak SharmaDSDeepak Sharma
- Lorri A. LeeLLLorri A. Lee
- Monica S. VavilalaMVMonica S. Vavilala
- 1 August 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 121 (2) , 492-501
Abstract
The effect of dexmedetomidine on evoked potentials (EPs) has not been elucidated. We aimed to investigate the effect of dexmedetomidine on somatosensory, motor, and visual EPs. After IRB approval, 40 adult patients scheduled for elective spine surgery using total IV anesthesia with propofol and remifentanil were randomly assigned to receive either dexmedetomidine (n = 20) or placebo (n = 20) in a double-blind, placebo-controlled trial. After obtaining informed consent, positioning, and baseline EPs recording, patients were randomly assigned to either IV dexmedetomidine 0.6 μg/kg infused over 10 minutes, followed by 0.6 μg/kg/h, or a corresponding volume of IV normal saline (placebo). EP measures at 60 ± 30 minutes after initiation of study drug were defined as T1 and at 150 ± 30 minutes were defined as T2. Changes from baseline to T1 (primary end point) and from baseline to T2 (secondary end point) in EP latencies (milliseconds) and amplitudes (microvolts) were compared between groups. Data presented as mean ± SD (95% confidence interval). Data from 40 patients (dexmedetomidine: n = 20; age, 54 ± 3 years; 10 males; placebo: n = 20; age, 52 ± 2 years; 5 males) were analyzed. There was no difference between dexmedetomidine versus placebo groups in primary end points: change of somatosensory EPs at T1, latency: 0.01 ± 1.3 (-0.64, 0.65) vs 0.01 ± 1.3 (-0.64, 0.65), P = 0.43 (-1.24, 0.45); amplitude: 0.03 ± 0.14 (-0.06, 0.02) vs -0.01 ± 0.13 (-0.07, 0.05), P = 0.76 (-0.074, 0.1); motor EPs amplitude at T1: 65.1 ± 194.8 (-35, 165; n = 18) vs 109.2 ± 241.4 (-24, 243; n = 16), P = 0.57 (-113.5, 241.57); visual EPs at T1 (right eye), amplitude: 2.3 ± 3.6 (-0.4, 5.1; n = 11) vs 0.3 ± 6.0 (-3.3, 3.9; n = 16), P = 0.38 (-6.7, 2.6); latency N1: 2.3 ± 3.6 (-0.4, 5.1) vs 0.3 ± 6.0 (-3.3, 3.9), P = 0.38 (-6.7, 2.6); latency P1: -1.6 ± 13.4 (-11.9, 8.7) vs -1.4 ± 8.1 (-6.3, 3.5), P = 0.97 (-9.3, 9.7) or secondary end points. There were no differences between right and left visual EPs either at T1 or at T2. In clinically relevant doses, dexmedetomidine as an adjunct to total IV anesthesia does not seem to alter EPs and therefore can be safely used during surgeries requiring monitoring of EPs.Keywords
This publication has 35 references indexed in Scilit:
- Lidocaine infusion adjunct to total intravenous anesthesia reduces the total dose of propofol during intraoperative neurophysiological monitoringJournal of Clinical Monitoring and Computing, 2013
- Neurophysiologic Intraoperative Monitoring of Olfactory and Optic NervesJournal Of Clinical Neurophysiology, 2011
- Susceptibility of Transcranial Electric Motor-evoked Potentials to Varying Targeted Blood Levels of Dexmedetomidine during Spine SurgeryAnesthesiology, 2010
- Highlights of Anesthetic Considerations for Intraoperative NeuromonitoringSeminars in Cardiothoracic and Vascular Anesthesia, 2010
- Standard and limitation of intraoperative monitoring of the visual evoked potentialActa Neurochirurgica, 2010
- Inhalational Anesthetics Induce Cell Damage by Disruption of Intracellular Calcium Homeostasis with Different PotenciesAnesthesiology, 2008
- The American Society of Anesthesiologists Postoperative Visual Loss RegistryAnesthesiology, 2006
- Observations on intraoperative monitoring of visual pathways using steady-state visual evoked potentialsEuropean Journal of Anaesthesiology, 2004
- Effects of physiological glucose on the pattern-VEP of healthy volunteersPhysiology & Behavior, 1995
- Monitoring optic nerve function during craniotomyJournal of Neurosurgery, 1976